[CAS NO. 2361289-44-1] CHIKV-IN-2
PRODUCTS SPECIFICATIONS [2361289-44-1]
DESCRIPTION [2361289-44-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 362.46 |
| Molecular Formula | C23H26N2O2 |
| SMILES | O=C(NC1=CC=C(C(C)(C)C#N)C=C1)C2=CC3=C(CCCCC3)C=C2OC |
Summary
CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV) , with excellent cellular antiviral activity ( EC 90 =270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydrogenase (DHODH) , which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools [1] .
In Vitro
CHIKV-IN-2 (compound 8q) is a potent pan-alphavirus inhibitor, with EC
90
s of 0.85-2.5 μM for CHIKV clinical isolates and attenuated vaccine strains
[1]
.
CHIKV-IN-2 is active against alphavirus VEEV (EC
90
=0.40 μM) as well as flaviviruses such as West Nile Virus (WNV, EC
90
=0.20 μM) and Dengue Virus Strain-2 (DENV-2, EC
90
=0.60 μM)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
CHIKV-IN-2 (compound 8q) (80 mg/kg; i.p. twice a day for 3 days) significantly decreases infectious CHIKV dissemination to other tissues of mice
[1]
.
CHIKV-IN-2 (40 mg/kg; p.o., i.p., s.c.) exhibits moderate bioavailability (F=41%, 43%, 4%), terminal elimination half-life (t
1/2
=9.9, 18.5, 18.6 h) and C
max
(642, 858, 90 ng/mL) in mice
[1]
.
CHIKV-IN-2 (1 mg/kg; i.v.) exhibits terminal elimination half-life (t
1/2
= 2.02 h) and AUC (497 h•ng/mL) in mice
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female and male C57BL/6 mice [1] |
| Dosage: | 80 mg/kg |
| Administration: | I.p. twice a day for 3 days |
| Result: |
Failed to inhibit virus loads at the site of infection.
Decreased virus dissemination to other tissues. |
| Animal Model: | Male C57BL/6 mice were challenged with CHIKV in the right footpad [1] |
| Dosage: | 1 mg/kg for i.v. and 40 mg/kg for p.o., i.p., s.c. (Pharmacokinetic Analysis) |
| Administration: | I.v., p.o., i.p., s.c. |
| Result: |
I.v.: t
1/2
= 2.02 h; AUC=497 h•ng/mL.
P.o.: F=41%; t 1/2 =9.9 h; C max =642 ng/mL. I.p.: F=43%; t 1/2 =18.5 h; C max =858 ng/mL. S.c.: F=4%; t 1/2 =18.6 h; C max =90 ng/mL. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 275.89 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7589 mL | 13.7946 mL | 27.5893 mL |
| 5 mM | 0.5518 mL | 2.7589 mL | 5.5179 mL |
| 10 mM | 0.2759 mL | 1.3795 mL | 2.7589 mL |